[1]
Cianferotti, L.; Marcocci, C. Subclinical vitamin D deficiency. Best Pract. Res. Clin. Endocrinol. Metab., 2012, 26, 523-537.
[2]
Iruzubieta, P.; Terán, Á.; Crespo, J.; Fábrega, E. Vitamin D deficiency in chronic liver disease. World J. Hepatol., 2014, 6, 901-915.
[3]
Reid, I.R. What diseases are causally linked to vitamin D deficiency? Arch. Dis. Child., 2016, 101, 185-189.
[4]
Alvarez, J.A.; Ashraf, A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int. J. Endocrinol., 2010, 2010, 351385.
[5]
Pacifico, L.; Anania, C.; Osborn, J.F.; Ferraro, F.; Bonci, E.; Olivero, E.; Chiesa, C. Low 25(OH)D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian children and adolescents. Eur. J. Endocrinol., 2011, 165, 603-611.
[6]
Forman, J.P.; Curhan, G.C.; Taylor, E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension, 2008, 52, 828-832.
[7]
Ju, S.Y.; Jeong, H.S.; Kim, D.H. Blood vitamin D status and metabolic syndrome in the general adult population: A dose-response meta-analysis. J. Clin. Endocrinol. Metab., 2014, 99, 1053-1063.
[8]
Al Mheid, I.; Patel, R.S.; Tangpricha, V.; Quyyumi, A.A. Vitamin D and cardiovascular disease: is the evidence solid? Eur. Heart J., 2013, 34, 3691-3698.
[9]
Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
[10]
Pacifico, L.; Poggiogalle, E.; Cantisani, V.; Menichini, G.; Ricci, P.; Ferraro, F.; Chiesa, C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J. Hepatol., 2010, 2, 275-288.
[11]
Rinella, M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015, 313, 2263-2273.
[12]
Tilg, H.; Moschen, A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab., 2008, 19, 371-379.
[13]
Stein, E.M.; Strain, G.; Sinha, N.; Ortiz, D.; Pomp, A.; Dakin, G.; McMahon, D.J.; Bockman, R.; Silverberg, S.J. Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study. Clin. Endocrinol. (Oxf.), 2009, 71, 176-183.
[14]
Hyppönen, E.; Boucher, B.J.; Berry, D.J.; Power, C. 25-hydroxy vitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes, 2008, 57, 298-305.
[15]
Liu, E.; Meigs, J.B.; Pittas, A.G.; McKeown, N.M.; Economos, C.D.; Booth, S.L.; Jacques, P.F. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J. Nutr., 2009, 139, 329-334.
[16]
Forouhi, N.G.; Luan, J.; Cooper, A.; Boucher, B.J.; Wareham, N.J. Baseline serum 25-hydroxyvitamin D is predictive of future glycaemic status and insulin resistance, the Medical Research Council Ely Prospective Study 1990-2000. Diabetes, 2008, 57, 2619-2625.
[17]
Kwok, R.M.; Torres, D.M.; Harrison, S.A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): It is more than just an association? Hepatology, 2013, 58, 1166-1174.
[18]
Targher, G.; Bertolini, L.; Scala, L.; Cigolini, M.; Zenari, L.; Falezza, G.; Arcaro, G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis., 2007, 17, 517-524.
[19]
Manco, M.; Ciampalini, P.; Nobili, V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology, 2010, 51, 2229.
[20]
Katz, K.; Brar, P.C.; Parekh, N.; Liu, Y.H.; Weitzman, M. Suspected nonalcoholic Fatty liver disease is not associated with vitamin d status in adolescents after adjustment for obesity. J. Obes., 2010, 2010, 496829.
[21]
Barchetta, I.; Angelico, F.; Del Ben, M.; Baroni, M.G.; Pozzilli, P.; Morini, S.; Cavallo, M.G. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med., 2011, 9, 85.
[22]
Liangpunsakul, S.; Chalasani, N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig. Dis. Sci., 2011, 56, 2124-2129.
[23]
Nseir, W.; Taha, H.; Khateeb, J.; Grosovski, M.; Assy, N. Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig. Dis. Sci., 2011, 56, 3328-3334.
[24]
Kayaniyil, S.; Vieth, R.; Harris, S.B.; Retnakaran, R.; Knight, J.A.; Gerstein, H.C.; Perkins, B.A.; Zinman, B.; Hanley, A.J. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J. Clin. Endocrinol. Metab., 2011, 96, 168-175.
[25]
Purnak, T.; Beyazit, Y.; Ozaslan, E.; Efe, C.; Hayretci, M. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien. Klin. Wochenschr., 2012, 124, 526-531.
[26]
Barchetta, I.; Carotti, S.; Labbadia, G.; Gentilucci, U.V.; Muda, A.O.; Angelico, F.; Silecchia, G.; Leonetti, F.; Fraioli, A.; Picardi, A.; Morini, S.; Cavallo, M.G. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology, 2012, 56, 2180-2187.
[27]
Bhatt, S.P.; Nigam, P.; Misra, A.; Guleria, R.; Qadar Pasha, M.A. Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with nonalcoholic fatty liver disease in Asian Indians residing in north India. Atherosclerosis, 2013, 230, 157-163.
[28]
Pirgon, O.; Cekmez, F.; Bilgin, H.; Eren, E.; Dundar, B. Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease. Obes. Res. Clin. Pract., 2013, 7, e275-e283.
[29]
Jablonski, K.L.; Jovanovich, A.; Holmen, J.; Targher, G.; McFann, K.; Kendrick, J.; Chonchol, M. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis., 2013, 23, 792-798.
[30]
Eraslan, S.; Kizilgul, M.; Uzunlulu, M.; Colak, Y.; Ozturk, O.; Tuncer, I. Frequency of metabolic syndrome and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver disease. Minerva Med., 2013, 104, 447-453.
[31]
Li, L.; Zhang, L.; Pan, S.; Wu, X.; Yin, X. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Dig. Dis. Sci., 2013, 58, 2376-2382.
[32]
Kasapoglu, B.; Turkay, C.; Yalcin, K.S.; Carlioglu, A.; Sozen, M.; Koktener, A. Low vitamin D levels are associated with increased risk for fatty liver disease among non-obese adults. Clin. Med. (Lond.), 2013, 13, 576-579.
[33]
Rhee, E.J.; Kim, M.K.; Park, S.E.; Park, C.Y.; Baek, K.H.; Lee, W.Y.; Kang, M.I.; Park, S.W.; Kim, S.W.; Oh, K.W. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr. J., 2013, 60, 743-752.
[34]
Seo, J.A.; Eun, C.R.; Cho, H.; Lee, S.K.; Yoo, H.J.; Kim, S.G.; Choi, K.M.; Baik, S.H.; Choi, D.S.; Yim, H.J.; Shin, C.; Kim, N.H. Low vitamin D status is associated with nonalcoholic Fatty liver disease independent of visceral obesity in Korean adults. PLoS One, 2013, 8, e75197.
[35]
Catena, C.; Cosma, C.; Camozzi, V.; Plebani, M.; Ermani, M.; Sechi, L.A.; Fallo, F. Non-alcoholic fatty liver disease is not associated with vitamin D deficiency in essential hypertension. High Blood Press. Cardiovasc. Prev., 2013, 20, 33-37.
[36]
Cui, R.; Sheng, H.; Rui, X.F.; Cheng, X.Y.; Sheng, C.J.; Wang, J.Y.; Qu, S. Low bone mineral density in chinese adults with nonalcoholic Fatty liver disease. Int. J. Endocrinol., 2013, 2013, 396545.
[37]
Nobili, V.; Giorgio, V.; Liccardo, D.; Bedogni, G.; Morino, G.; Alisi, A.; Cianfarani, S. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur. J. Endocrinol., 2014, 170, 547-553.
[38]
Black, L.J.; Jacoby, P.; She Ping-Delfos, W.C.; Mori, T.A.; Beilin, L.J.; Olynyk, J.K.; Ayonrinde, O.T.; Huang, R.C.; Holt, P.G.; Hart, P.H.; Oddy, W.H.; Adams, L.A. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J. Gastroenterol. Hepatol., 2014, 29, 1215-1222.
[39]
Dasarathy, J.; Periyalwar, P.; Allampati, S.; Bhinder, V.; Hawkins, C.; Brandt, P.; Khiyami, A.; McCullough, A.J.; Dasarathy, S. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int., 2014, 34, e118-e127.
[40]
Hao, Y.P.; Ma, X.J.; Luo, Y.Q.; Ni, J.; Dou, J.X.; Hu, Y.Q.; Zhu, J.A.; Bao, Y.Q.; Jia, W.P. Serum vitamin D is associated with non-alcoholic fatty liver disease in Chinese males with normal weight and liver enzymes. Acta Pharmacol. Sin., 2014, 35, 1150-1156.
[41]
Küçükazman, M.; Ata, N.; Dal, K.; Yeniova, A.Ö.; Kefeli, A.; Basyigit, S.; Aktas, B.; Akin, K.O.; Ağladıoğlu, K.; Üre, Ö.S.; Topal, F.; Nazligül, Y.; Beyan, E.; Ertugrul, D.T. The association of vitamin D deficiency with non-alcoholic fatty liver disease. Clinics (São Paulo), 2014, 69, 542-546.
[42]
Díez Rodríguez, R.; Ballesteros Pomar, M.D.; Calleja Fernández, A.; Calleja Antolin, S.; Cano Rodríguez, I.; Linares Torres, P.; Jorquera Plaza, F.; Olcoz Goñi, J.L. Vitamin D levels and bone turnover markers are not related to non-alcoholic fatty liver disease in severely obese patients. Nutr. Hosp., 2014, 30, 1256-1262.
[43]
Jeong, D.W.; Lee, H.W.; Cho, Y.H.; Yi, D.W.; Lee, S.Y.; Son, S.M.; Kang, Y.H. Comparison of serum ferritin and vitamin D in association with the severity of nonalcoholic Fatty liver disease in korean adults. Endocrinol. Metab. (Seoul), 2014, 29, 479-488.
[44]
Yildiz, I.; Erol, O.B.; Toprak, S.; Cantez, M.S.; Omer, B.; Kilic, A.; Oguz, F.; Uysalol, M.; Yekeler, E.; Unuvar, E. Role of vitamin D in children with hepatosteatosis. J. Pediatr. Gastroenterol. Nutr., 2014, 59, 106-111.
[45]
Hourigan, S.K.; Abrams, S.; Yates, K.; Pfeifer, K.; Torbenson, M.; Murray, K.; Roth, C.L.; Kowdley, K.; Scheimann, A.O. NASH CRN. Relation between vitamin D status and nonalcoholic fatty liver disease in children. J. Pediatr. Gastroenterol. Nutr., 2015, 60, 396-404.
[46]
Chang, E.J.; Yi, D.Y.; Yang, H.R.; Vitamin, D. Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. J. Korean Med. Sci., 2015, 30, 1821-1827.
[47]
Bril, F.; Maximos, M.; Portillo-Sanchez, P.; Biernacki, D.; Lomonaco, R.; Subbarayan, S.; Correa, M.; Lo, M.; Suman, A.; Cusi, K. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J. Hepatol., 2015, 62, 405-411.
[48]
Lu, Z.; Pan, X.; Hu, Y.; Hao, Y.; Luo, Y.; Hu, X.; Ma, X.; Bao, Y.; Jia, W. Serum vitamin D levels are inversely related with non-alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women. Clin. Exp. Pharmacol. Physiol., 2015, 42, 139-145.
[49]
Malespin, M.; Sleesman, B.; Lau, A.; Wong, S.S.; Cotler, S.J. Prevalence and correlates of suspected nonalcoholic fatty liver disease in Chinese American children. J. Clin. Gastroenterol., 2015, 49, 345-349.
[50]
Anty, R.; Hastier, A.; Canivet, C.M.; Patouraux, S.; Schneck, A.S.; Ferrari-Panaia, P.; Ben-Amor, I.; Saint-Paul, M.C.; Gugenheim, J.; Gual, P.; Iannelli, A.; Tran, A. Severe Vitamin D deficiency is not associated with liver damage in morbidly obese patients. Obes. Surg., 2016, 26, 2138-2143.
[51]
Wang, N.; Zhai, H.; Zhu, C.; Li, Q.; Han, B.; Chen, Y.; Zhu, C.; Chen, Y.; Xia, F.; Lin, D.; Lu, Y. Combined association of vitamin d and sex hormone binding globulin with nonalcoholic fatty liver disease in men and postmenopausal women: A cross-sectional study. Medicine (Baltimore), 2016, 95, e2621.
[52]
Zhai, H.L.; Wang, N.J.; Han, B.; Li, Q.; Chen, Y.; Zhu, C.F.; Chen, Y.C.; Xia, F.Z.; Cang, Z.; Zhu, C.X.; Lu, M. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: A cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China). Br. J. Nutr., 2016, 115, 1352-1359.
[53]
Nelson, J.E.; Roth, C.L.; Wilson, L.A.; Yates, K.P.; Aouizerat, B.; Morgan-Stevenson, V.; Whalen, E.; Hoofnagle, A.; Mason, M.; Gersuk, V.; Yeh, M.M.; Kowdley, K.V. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: Possible role for MAPK and NF-κB? Am. J. Gastroenterol., 2016, 111, 852-863.
[54]
Luger, M.; Kruschitz, R.; Kienbacher, C.; Traussnigg, S.; Langer, F.B.; Schindler, K.; Würger, T.; Wrba, F.; Trauner, M.; Prager, G.; Ludvik, B. Prevalence of liver fibrosis and its association with non-invasive fibrosis and metabolic markers in morbidly obese Patients with Vitamin D deficiency. Obes. Surg., 2016, 26, 2425-2432.
[55]
Chung, G.E.; Kim, D.; Kwak, M.S.; Yang, J.I.; Yim, J.Y.; Lim, S.H.; Itani, M. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol., 2016, 22, 146-151.
[56]
Sezer, O.B.; Buluş, D.; Hızlı, Ş.; Andıran, N.; Yılmaz, D.; Ramadan, S.U. Low 25-hydroxyvitamin D level is not an independent risk factor for hepatosteatosis in obese children. J. Pediatr. Endocrinol. Metab., 2016, 29, 783-788.
[57]
Wang, D.; Lin, H.; Xia, M.; Aleteng, Q.; Li, X.; Ma, H.; Pan, B.; Gao, J.; Gao, X. Vitamin D levels are inversely associated with liver fat content and risk of non-alcoholic fatty liver disease in a chinese middle-aged and elderly population: The shanghai changfeng study. PLoS One, 2016, 11, e0157515.
[58]
Polyzos, S.A.; Anastasilakis, A.D.; Kountouras, J.; Makras, P.; Papatheodorou, A.; Kokkoris, P.; Sakellariou, G.T.; Terpos, E. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J. Bone Miner. Metab., 2016, 34, 447-456.
[59]
Patel, Y.A.; Henao, R.; Moylan, C.A.; Guy, C.D.; Piercy, D.L.; Diehl, A.M.; Abdelmalek, M.F. Vitamin D is not associated with severity in nafld: Results of a paired clinical and gene expression profile analysis. Am. J. Gastroenterol., 2016, 111, 1591-1598.
[60]
Mohamed, A. A.; Ghany, M.A.; Hakeem, G.L.; Mostafa, A.; Khattab, R.A.; Abdalla, A.M.; El Fotoh, L.E.; El Mazary, A.A.; Sayed, M.A.; Fadil, A.M. Assessment of Vitamin D status in a group of Egyptian children with non alcoholic fatty liver disease (multicenter study). Nutr. Metab. (Lond.), 2016, 13, 83.
[61]
Park, D.; Kwon, H.; Oh, S.W.; Joh, H.K.; Hwang, S.S.; Park, J.H.; Yun, J.M.; Lee, H.; Chung, G.E.; Ze, S.; Park, J.H.; Bae, Y.; Lee, A. Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: A Cross-Sectional study of the healthy population. J. Korean Med. Sci., 2017, 32, 95-101.
[62]
Yang, B.B.; Chen, Y.H.; Zhang, C.; Shi, C.E.; Hu, K.F.; Zhou, J.; Xu, D.X.; Chen, X. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease. Endocrine, 2017, 55, 582-590.
[63]
Eliades, M.; Spyrou, E.; Agrawal, N.; Lazo, M.; Brancati, F.L.; Potter, J.J.; Koteish, A.A.; Clark, J.M.; Guallar, E.; Hernaez, R. Meta-analysis: Vitamin D and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 2013, 38, 246-254.
[64]
Holick, M.F.; Vitamin, D. Extraskeletal health. Endocrinol. Metab. Clin. North Am., 2010, 39, 381-400.
[65]
Holick, M.F.; Vitamin, D. A d-lightful solution for health. J. Investig. Med., 2011, 59, 872-880.
[66]
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med., 2007, 357, 266-281.
[67]
Kitson, M.T.; Roberts, S.K. D-livering the message: The importance of vitamin D status in chronic liver disease. J. Hepatol., 2012, 57, 897-909.
[68]
Borel, P.; Caillaud, D.; Cano, N.J. Vitamin D bioavailability: State of the art. Crit. Rev. Food Sci. Nutr., 2015, 55, 1193-1205.
[69]
Armas, L.A.; Hollis, B.W.; Heaney, R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab., 2004, 89, 5387-5391.
[70]
Jassil, N.K.; Sharma, A.; Bikle, D.; Wang, X. Vitamin D binding protein and 25-hy droxyvitamin D levels: Emerging clinical applications. Endocr. Pract., 2017, 23, 605-613.
[71]
Kamboh, M.I.; Ferrell, R.E. Ethnic variation in vitamin D-binding protein (GC): A review of isoelectric focusing studies in human populations. Hum. Genet., 1986, 72, 281-293.
[72]
Bhan, I. Vitamin d binding protein and bone health. Int. J. Endocrinol., 2014, 2014, 561214.
[73]
Johnsen, M.S.; Grimnes, G.; Figenschau, Y.; Torjesen, P.A.; Almås, B.; Jorde, R. Serum free and bio-available 25-hydroxyvitamin D correlate better with bone density than serum total 25-hydroxyvitamin D. Scand. J. Clin. Lab. Invest., 2014, 74, 177-183.
[74]
Yamamoto, N.; Homma, S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc. Natl. Acad. Sci. USA, 1991, 88, 8539-8543.
[75]
Metcalf, J.P.; Thompson, A.B.; Gossman, G.L.; Nelson, K.J.; Koyama, S.; Rennard, S.I.; Robbins, R.A. Gcglobulin functions as a cochemotaxin in the lower respiratory tract. A potential mechanism for lung neutrophil recruitment in cigarette smokers. Am. Rev. Respir. Dis., 1991, 143(4 Pt 1), 844-849.
[76]
White, P.; Cooke, N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol. Metab., 2000, 11, 320-327.
[77]
Van Belle, T.L.; Gysemans, C.; Mathieu, C. Vitamin D in autoimmune, infectious and allergic diseases: A vital player? Best Pract. Res. Clin. Endocrinol. Metab., 2011, 25, 617-632.
[78]
Mora, J.R.; Iwata, M.; von Andrian, U.H. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat. Rev. Immunol., 2008, 8, 685-698.
[79]
Bookout, A.L.; Jeong, Y.; Downes, M.; Yu, R.T.; Evans, R.M.; Mangelsdorf, D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell, 2006, 126, 789-799.
[80]
Messa, P.; Alfieri, C.; Rastaldi, M.P. Recent insights into vitamin D and its receptor. J. Nephrol., 2011, 24(Suppl. 18), S30-S37.
[81]
Webb, A.R.; DeCosta, B.R.; Holick, M.F. Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation. J. Clin. Endocrinol. Metab., 1989, 68, 882-887.
[82]
Cranney, A.; Weiler, H.A.; O’Donnell, S.; Puil, L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am. J. Clin. Nutr., 2008, 88(Suppl.), S513-S519.
[83]
Rapuri, P.B.; Kinyamu, H.K.; Gallagher, J.C.; Haynatzka, V. Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women. J. Clin. Endocrinol. Metab., 2002, 87, 2024-2032.
[84]
van der Mei, I.A.; Ponsonby, A.L.; Engelsen, O.; Pasco, J.A.; McGrath, J.J.; Eyles, D.W.; Blizzard, L.; Dwyer, T.; Lucas, R.; Jones, G. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ. Health Perspect., 2007, 115, 1132-1139.
[85]
Kull, M., Jr; Kallikorm, R.; Tamm, A.; Lember, M. Seasonal variance of 25-(OH) vitamin D in the general population of Estonia, a Northern European country. BMC Public Health, 2009, 9, 22.
[86]
Harris, S.S.; Dawson-Hughes, B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am. J. Clin. Nutr., 1998, 67, 1232-1236.
[87]
Dawson-Hughes, B.; Harris, S.S.; Dallal, G.E. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am. J. Clin. Nutr., 1997, 65, 67-71.
[88]
Tangpricha, V.; Pearce, E.N.; Chen, T.C.; Holick, M.F. Vitamin D insufficiency among free-living healthy young adults. Am. J. Med., 2002, 112, 659-662.
[89]
Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Overview of Vitamin D. In: Dietary Reference Intakes for Vitamin D and Calcium; A.C.; Ross.; C.L. Taylor.; A.L. Yaktine.; H.B. Del Valle., Eds. National Academies Press (US): Washington (DC), 2011; pp. 75-124.
[90]
Nesby-O’Dell, S.; Scanlon, K.S.; Cogswell, M.E.; Gillespie, C.; Hollis, B.W.; Looker, A.C.; Allen, C.; Doughertly, C.; Gunter, E.W.; Bowman, B.A. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third national health and nutrition examination survey, 1988-1994. Am. J. Clin. Nutr., 2002, 76, 187-192.
[91]
Brazerol, W.F.; McPhee, A.J.; Mimouni, F.; Specker, B.L.; Tsang, R.C. Serial ultraviolet B exposure and serum 25 hydroxyvitamin D response in young adult American blacks and whites: No racial differences. J. Am. Coll. Nutr., 1988, 7, 111-118.
[92]
Rockell, J.E.; Skeaff, C.M.; Williams, S.M.; Green, T.J. Association between quantitative measures of skin color and plasma 25-hydroxyvitamin D. Osteoporos. Int., 2008, 19, 1639-1642.
[93]
Marks, R.; Foley, P.A.; Jolley, D.; Knight, K.R.; Harrison, J.; Thompson, S.C. The effect of regular sunscreen use on vitamin D levels in an australian population. Results of a randomized controlled trial. Arch. Dermatol., 1995, 131, 415-421.
[94]
Bogh, M.K.; Schmedes, A.V.; Philipsen, P.A.; Thieden, E.; Wulf, H.C. Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation. J. Invest. Dermatol., 2010, 130, 546-553.
[95]
Snellman, G.; Melhus, H.; Gedeborg, R.; Olofsson, S.; Wolk, A.; Pedersen, N.L.; Michaëlsson, K. Seasonal genetic influence on serum 25-hydroxyvitamin D levels: A twin study. PLoS One, 2009, 4, e7747.
[96]
Kimlin, M.G.; Olds, W.J.; Moore, M.R. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J. Photochem. Photobiol. B, 2007, 86, 234-239.
[97]
Lubin, D.; Jensen, E.H.; Gies, H.P. Global surface ultraviolet radiation climatology from TOMS and ERBE data. JGR-Atmospheres, 1998, 103, 26061-26091.
[98]
Lund, B.; Sørensen, O.H. Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population. Scand. J. Clin. Lab. Invest., 1979, 39, 23-30.
[99]
Baker, M.R.; Peacock, M.; Nordin, B.E. The decline in vitamin D status with age. Age Ageing, 1980, 9, 249-252.
[100]
Maclaughlin, J.; Holick, M.F. Aging decreases the capacity of human skin to produce vitamin D3. J. Clin. Invest., 1985, 76, 1536-1538.
[101]
Cardinez, C.J.; Cokkinides, V.E.; Weinstock, M.A.; O’Connell, M.C. Sun protective behaviors and sunburn experiences in parents of youth ages 11 to 18. Prev. Med., 2005, 41, 108-111.
[102]
DiSipio, T.; Rogers, C.; Newman, B.; Whiteman, D.; Eakin, E.; Fritschi, L.; Aitken, J. The Queensland Cancer Risk Study: Behavioural risk factor results. Aust. N. Z. J. Public Health, 2006, 30, 375-382.
[103]
Brock, K.; Huang, W.Y.; Fraser, D.R.; Ke, L.; Tseng, M.; Stolzenberg-Solomon, R.; Peters, U.; Ahn, J.; Purdue, M.; Mason, R.S.; McCarty, C.; Ziegler, R.G.; Graubard, B. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. J. Steroid Biochem. Mol. Biol., 2010, 121, 462-466.
[104]
Touvier, M.; Deschasaux, M.; Montourcy, M.; Sutton, A.; Charnaux, N.; Kesse-Guyot, E.; Assmann, K.E.; Fezeu, L.; Latino-Martel, P.; Druesne-Pecollo, N.; Guinot, C.; Latreille, J.; Malvy, D.; Galan, P.; Hercberg, S.; Le Clerc, S.; Souberbielle, J.C.; Ezzedine, K. Determinants of vitamin D status in caucasian adults: Influence of sun exposure, dietary intake, sociodemographic, lifestyle, anthropometric, and genetic factors. J. Invest. Dermatol., 2015, 135, 378-388.
[105]
Freedman, D.M.; Cahoon, E.K.; Rajaraman, P.; Major, J.M.; Doody, M.M.; Alexander, B.H.; Hoffbeck, R.W.; Kimlin, M.G.; Graubard, B.I.; Linet, M.S. Sunlight and other determinants of circulating 25-hydroxyvitamin D levels in black and white participants in a nationwide U.S. study. Am. J. Epidemiol., 2013, 177, 180-192.
[106]
Mithal, A.; Wahl, D.A.; Bonjour, J.P.; Burckhardt, P.; Dawson-Hughes, B.; Eisman, J.A.; El-Hajj Fuleihan, G.; Josse, R.G.; Lips, P.; Morales-Torres, J. IOF committee of scientific advisors (CSA) nutrition working group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int., 2009, 20, 1807-1820.
[107]
McCullough, M.L.; Weinstein, S.J.; Freedman, D.M.; Helzlsouer, K.; Flanders, W.D.; Koenig, K.; Kolonel, L.; Laden, F.; Le Marchand, L.; Purdue, M.; Snyder, K.; Stevens, V.L.; Stolzenberg-Solomon, R.; Virtamo, J.; Yang, G.; Yu, K.; Zheng, W.; Albanes, D.; Ashby, J.; Bertrand, K.; Cai, H.; Chen, Y.; Gallicchio, L.; Giovannucci, E.; Jacobs, E.J.; Hankinson, S.E.; Hartge, P.; Hartmuller, V.; Harvey, C.; Hayes, R.B.; Horst, R.L.; Shu, X.O. Correlates of circulating 25-hydroxyvitamin D: Cohort consortium vitamin d pooling project of rarer cancers. Am. J. Epidemiol., 2010, 172, 21-35.
[108]
Hyppönen, E.; Power, C. Hypovitaminosis D in British adults at age 45 y: Nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr., 2007, 85, 860-868.
[109]
van Dam, R.M.; Snijder, M.B.; Dekker, J.M.; Stehouwer, C.D.; Bouter, L.M.; Heine, R.J.; Lips, P. Potentially modifiable determinants of vitamin D status in an older population in the Netherlands: The Hoorn Study. Am. J. Clin. Nutr., 2007, 85, 755-761.
[110]
Chan, J.; Jaceldo-Siegl, K.; Fraser, G.E. Determinants of serum 25 hydroxyvitamin D levels in a nationwide cohort of blacks and non-Hispanic whites. Cancer Causes Control, 2010, 21, 501-511.
[111]
Harris, S.S.; Soteriades, E.; Coolidge, J.A.; Mudgal, S.; Dawson-Hughes, B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J. Clin. Endocrinol. Metab., 2000, 85, 4125-4130.
[112]
Hilger, J.; Friedel, A.; Herr, R.; Rausch, T.; Roos, F.; Wahl, D.A.; Pierroz, D.D.; Weber, P.; Hoffmann, K. A systematic review of vitamin D status in populations worldwide. Br. J. Nutr., 2014, 111, 23-45.
[113]
Batieha, A.; Khader, Y.; Jaddou, H.; Hyassat, D.; Batieha, Z.; Khateeb, M.; Belbisi, A.; Ajlouni, K. Vitamin D status in Jordan: Dress style and gender discrepancies. Ann. Nutr. Metab., 2011, 58, 10-18.
[114]
Gannagé-Yared, M.H.; Chemali, R.; Yaacoub, N.; Halaby, G. Hypovitaminosis D in a sunny country: Relation to lifestyle and bone markers. J. Bone Miner. Res., 2000, 15, 1856-1862.
[115]
El-Hajj Fuleihan, G.; Nabulsi, M.; Choucair, M.; Salamoun, M.; Hajj Shahine, C.; Kizirian, A.; Tannous, R. Hypovitaminosis D in healthy schoolchildren. Pediatrics, 2001, 107, E53.
[116]
Meddeb, N.; Sahli, H.; Chahed, M.; Abdelmoula, J.; Feki, M.; Salah, H.; Frini, S.; Kaabachi, N.; Belkahia, Ch.; Mbazaa, R.; Zouari, B.; Sellami, S. Vitamin D deficiency in Tunisia. Osteoporos. Int., 2005, 16, 180-183.
[117]
el-Sonbaty, M.R.; Abdul-Ghaffar, N.U. Vitamin D deficiency in veiled Kuwaiti women. Eur. J. Clin. Nutr., 1996, 50, 315-318.
[118]
Green, T.J.; Skeaff, C.M.; Rockell, J.E.; Venn, B.J.; Lambert, A.; Todd, J.; Khor, G.L.; Loh, S.P.; Muslimatun, S.; Agustina, R.; Whiting, S.J. Vitamin D status and its association with parathyroid hormone concentrations in women of child-bearing age living in Jakarta and Kuala Lumpur. Eur. J. Clin. Nutr., 2008, 62, 373-378.
[119]
Islam, M.Z.; Lamberg-Allardt, C.; Kärkkäinen, M.; Outila, T.; Salamatullah, Q.; Shamim, A.A. Vitamin D deficiency: A concern in premenopausal Bangladeshi women of two socio-economic groups in rural and urban region. Eur. J. Clin. Nutr., 2002, 56, 51-56.
[120]
Allali, F.; El Aichaoui, S.; Khazani, H.; Benyahia, B.; Saoud, B.; El Kabbaj, S.; Bahiri, R.; Abouqal, R.; Hajjaj-Hassouni, N. High prevalence of hypovitaminosis D in Morocco: Relationship to lifestyle, physical performance, bone markers, and bone mineral density. Semin. Arthritis Rheum., 2009, 38, 444-451.
[121]
Hunter, D.; De Lange, M.; Snieder, H.; MacGregor, A.J.; Swaminathan, R.; Thakker, R.V.; Spector, T.D. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J. Bone Miner. Res., 2001, 16, 371-378.
[122]
Shea, M.K.; Benjamin, E.J.; Dupuis, J.; Massaro, J.M.; Jacques, P.F.; D’Agostino, R.B., Sr; Ordovas, J.M.; O’Donnell, C.J.; Dawson-Hughes, B.; Vasan, R.S.; Booth, S.L. Genetic and non-genetic correlates of vitamins K and D. Eur. J. Clin. Nutr., 2009, 63, 458-464.
[123]
Wang, T.J.; Zhang, F.; Richards, J.B.; Kestenbaum, B.; van Meurs, J.B.; Berry, D.; Kiel, D.P.; Streeten, E.A.; Ohlsson, C.; Koller, D.L.; Peltonen, L.; Cooper, J.D.; O’Reilly, P.F.; Houston, D.K.; Glazer, N.L.; Vandenput, L.; Peacock, M.; Shi, J.; Rivadeneira, F.; McCarthy, M.I.; Anneli, P.; de Boer, I.H.; Mangino, M.; Kato, B.; Smyth, D.J.; Booth, S.L.; Jacques, P.F.; Burke, G.L.; Goodarzi, M.; Cheung, C.L.; Wolf, M.; Rice, K.; Goltzman, D.; Hidiroglou, N.; Ladouceur, M.; Wareham, N.J.; Hocking, L.J.; Hart, D.; Arden, N.K.; Cooper, C.; Malik, S.; Fraser, W.D.; Hartikainen, A.L.; Zhai, G.; Macdonald, H.M.; Forouhi, N.G.; Loos, R.J.; Reid, D.M.; Hakim, A.; Dennison, E.; Liu, Y.; Power, C.; Stevens, H.E.; Jaana, L.; Vasan, R.S.; Soranzo, N.; Bojunga, J.; Psaty, B.M.; Lorentzon, M.; Foroud, T.; Harris, T.B.; Hofman, A.; Jansson, J.O.; Cauley, J.A.; Uitterlinden, A.G.; Gibson, Q.; Järvelin, M.R.; Karasik, D.; Siscovick, D.S.; Econs, M.J.; Kritchevsky, S.B.; Florez, J.C.; Todd, J.A.; Dupuis, J.; Hyppönen, E.; Spector, T.D. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet, 2010, 376, 180-188.
[124]
Ahn, J.; Yu, K.; Stolzenberg-Solomon, R.; Simon, K.C.; McCullough, M.L.; Gallicchio, L.; Jacobs, E.J.; Ascherio, A.; Helzlsouer, K.; Jacobs, K.B.; Li, Q.; Weinstein, S.J.; Purdue, M.; Virtamo, J.; Horst, R.; Wheeler, W.; Chanock, S.; Hunter, D.J.; Hayes, R.B.; Kraft, P.; Albanes, D. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet., 2010, 19, 2739-2745.
[125]
Powe, C.E.; Evans, M.K.; Wenger, J.; Zonderman, A.B.; Berg, A.H.; Nalls, M.; Tamez, H.; Zhang, D.; Bhan, I.; Karumanchi, S.A.; Powe, N.R.; Thadhani, R. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med., 2013, 369, 1991-2000.
[126]
Carter, G.D. Accuracy of 25-hydroxyvitamin D assays: Confronting the issues. Curr. Drug Targets, 2011, 12, 19-28.
[127]
Binkley, N.; Wiebe, D. Clinical controversies in vitamin D: 25(OH)D measurement, target concentration, and supplementation. J. Clin. Densitom., 2013, 16, 402-408.
[128]
Bikle, D.; Bouillon, R.; Thadhani, R.; Schoenmakers, I. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status? J. Steroid Biochem. Mol. Biol., 2017, 173, 105-116.
[129]
Thacher, T.D.; Clarke, B.L. Vitamin D insufficiency. Mayo Clin. Proc., 2011, 86, 50-60.
[130]
Su, Z.; Narla, S.N.; Zhu, Y. Hydroxyvitamin D: analysis and clinical application. Clin. Chim. Acta, 2014, 433, 200-205.
[131]
Cannell, J.J.; Hollis, B.W. Use of vitamin D in clinical practice. Altern. Med. Rev., 2008, 13, 6-20.
[132]
Dawson-Hughes, B.; Heaney, R.P.; Holick, M.F.; Lips, P.; Meunier, P.J.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos. Int., 2005, 16, 713-716.
[133]
Bouillon, R. Why modest but widespread improvement of the vitamin D status is the best strategy? Best Pract. Res. Clin. Endocrinol. Metab., 2011, 25, 693-702.
[134]
Chapuy, M.C.; Preziosi, P.; Maamer, M.; Arnaud, S.; Galan, P.; Hercberg, S.; Meunier, P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int., 1997, 7, 439-443.
[135]
Rosen, C.J. Vitamin D insufficiency. N. Engl. J. Med., 2011, 364, 248-254.
[136]
Heaney, R.P.; Dowell, M.S.; Hale, C.A.; Bendich, A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr., 2003, 22, 142-146.
[137]
Ooms, M.E.; Lips, P.; Roos, J.C.; van der Vijgh, W.J.; Popp-Snijders, C.; Bezemer, P.D.; Bouter, L.M. Vitamin D status and sex hormone binding globulin: Determinants of bone turnover and bone mineral density in elderly women. J. Bone Miner. Res., 1995, 10, 1177-1184.
[138]
Lips, P.; Duong, T.; Oleksik, A.; Black, D.; Cummings, S.; Cox, D.; Nickelsen, T. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab., 2001, 86, 1212-1221.
[139]
Bischoff-Ferrari, H.A.; Dietrich, T.; Orav, E.J.; Dawson-Hughes, B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. Am. J. Med., 2004, 116, 634-639.
[140]
Vieth, R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml). Best Pract. Res. Clin. Endocrinol. Metab., 2011, 25, 681-691.
[141]
Priemel, M.; von Domarus, C.; Klatte, T.O.; Kessler, S.; Schlie, J.; Meier, S.; Proksch, N.; Pasto, F.; Netter, C.; Streichert, T.; Püschel, K.; Amling, M. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res., 2010, 25, 305-312.
[142]
Holick, M.F. Vitamin D status: Measurement, interpretation, and clinical application. Ann. Epidemiol., 2009, 19, 73-78.
[143]
Cianferotti, L.; Bertoldo, F.; Bischoff-Ferrari, H.A.; Bruyere, O.; Cooper, C.; Cutolo, M.; Kanis, J.A.; Kaufman, J.M.; Reginster, J.Y.; Rizzoli, R.; Brandi, M.L. Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.
[144]
Bischoff-Ferrari, H.A.; Giovannucci, E.; Willett, W.C.; Dietrich, T.; Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr., 2006, 84, 18-28.
[145]
Hollis, B.W.; Napoli, J.L. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin. Chem., 1985, 31, 1815-1819.
[146]
Farrell, C.J.; Martin, S.; McWhinney, B.; Straub, I.; Williams, P.; Herrmann, M. State-of-the-art vitamin D assays: A comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin. Chem., 2012, 58, 531-542.
[147]
Lai, J.K.; Lucas, R.M.; Clements, M.S.; Harrison, S.L.; Banks, E. Assessing vitamin D status: Pitfalls for the unwary. Mol. Nutr. Food Res., 2010, 54, 1062-1071.
[148]
Carter, G.D.; Jones, J.C.; Berry, J.L. The anomalous behaviour of exogenous 25-hydroxyvitamin D in competitive binding assays. J. Steroid Biochem. Mol. Biol., 2007, 103, 480-482.
[149]
Herrmann, M.; Harwood, T.; Gaston-Parry, O.; Kouzios, D.; Wong, T.; Lih, A.; Jimenez, M.; Janu, M.; Seibel, M.J. A new quantitative LC tandem mass spectrometry assay for serum 25-hydroxy vitamin D. Steroids, 2010, 75, 1106-1112.
[150]
Carter, G.D. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin. Chem., 2009, 55, 1300-1302.
[151]
Hollis, B.W. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin. Chem., 2000, 46, 1657-1661.
[152]
Singh, R.J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D? Clin. Chem., 2008, 54, 221-223.
[153]
Fraser, W.D.; Milan, A.M. Vitamin D assays: past and present debates, difficulties, and developments. Calcif. Tissue Int., 2013, 92, 118-127.
[154]
Vogeser, M. Quantification of circulating 25-hydroxyvitamin D by liquid chromatography tandem mass spectrometry. J. Steroid Biochem. Mol. Biol., 2010, 121, 565-573.
[155]
Wallace, A.M.; Gibson, S.; de la Hunty, A.; Lamberg-Allardt, C.; Ashwell, M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids, 2010, 75, 477-488.
[156]
Beastall, G.; Rainbow, S. Vitamin D reinvented: implications for clinical chemistry. Clin. Chem., 2008, 54, 630-632.
[157]
Heijboer, A.C.; Blankenstein, M.A.; Kema, I.P.; Buijs, M.M. Accuracy of 6 routine 25-hydroxyvitamin D assays: Influence of vitamin D binding protein concentration. Clin. Chem., 2012, 58, 543-548.
[158]
de Koning, L.; Al-Turkmani, M.R.; Berg, A.H.; Shkreta, A.; Law, T.; Kellogg, M.D. Variation in clinical vitamin D status by DiaSorin Liaison and LC-MS/MS in the presence of elevated 25-OH vitamin D2. Clin. Chim. Acta, 2013, 415, 54-58.
[159]
Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; Kovacs, C.S.; Mayne, S.T.; Rosen, C.J.; Shapses, S.A. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: What clinicians need to know. J. Clin. Endocrinol. Metab., 2011, 96, 53-58.
[160]
Terry, A.H.; Sandrock, T.; Meikle, A.W. Measurement of 25-hydroxyvitamin D by the Nichols ADVANTAGE, DiaSorin LIAISON, DiaSorin RIA, and liquid chromatography-tandem mass spectrometry. Clin. Chem., 2005, 51, 1565-1566.
[161]
Glendenning, P.; Taranto, M.; Noble, J.M.; Musk, A.A.; Hammond, C.; Goldswain, P.R.; Fraser, W.D.; Vasikaran, S.D. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem., 2006, 43(Pt 1), 23-30.
[162]
Binkley, N.; Krueger, D.; Lensmeyer, G. 25-hydroxyvitamin D measurement, 2009: a review for clinicians. J. Clin. Densitom., 2009, 12, 417-427.
[163]
Carter, G.D.; Carter, R.; Jones, J.; Berry, J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin. Chem., 2004, 50, 2195-2197.
[164]
Bailey, D.; Veljkovic, K.; Yazdanpanah, M.; Adeli, K. Analytical measurement and clinical relevance of vitamin D(3) C3-epimer. Clin. Biochem., 2013, 46, 190-196.
[165]
Singh, R.J.; Taylor, R.L.; Reddy, G.S.; Grebe, S.K. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J. Clin. Endocrinol. Metab., 2006, 91, 3055-3061.
[166]
Kamao, M.; Tatematsu, S.; Sawada, N.; Sakaki, T.; Hatakeyama, S.; Kubodera, N.; Okano, T. Cell specificity and properties of the C-3 epimerization of Vitamin D3 metabolites. J. Steroid Biochem. Mol. Biol., 2004, 89-90, 39-42.
[167]
Kamao, M.; Tatematsu, S.; Hatakeyama, S.; Sakaki, T.; Sawada, N.; Inouye, K.; Ozono, K.; Kubodera, N.; Reddy, G.S.; Okano, T. C-3 epimerization of Vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1 or C-24 hydroxylation. J. Biol. Chem., 2004, 279, 15897-15907.
[168]
Stepman, H.C.; Vanderroost, A.; Stöckl, D.; Thienpont, L.M. Full-scan mass spectral evidence for 3-epi-25-hydroxyvitamin D3 in serum of infants and adults. Clin. Chem. Lab. Med., 2011, 49, 253-256.
[169]
Shah, I.; James, R.; Barker, J.; Petroczi, A.; Naughton, D.P. Misleading measures in Vitamin D analysis: A novel LC-MS/MS assay to account for epimers and isobars. Nutr. J., 2011, 10, 46.
[170]
Lensmeyer, G.; Poquette, M.; Wiebe, D.; Binkley, N. The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J. Clin. Endocrinol. Metab., 2012, 97, 163-168.
[171]
Volmer, D.A.; Mendes, L.R.; Stokes, C.S. Analysis of vitamin D metabolic markers by mass spectrometry: current techniques, limitations of the “gold standard” method, and anticipated future directions. Mass Spectrom. Rev., 2015, 34, 2-23.
[172]
Hollis, B.W. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am. J. Clin. Nutr., 2008, 88(Suppl.), S507-S510.
[173]
Binkley, N.; Drezner, M.K.; Hollis, B.W. Laboratory reporting of 25-hydroxyvitamin D results: Potential for clinical misinterpretation. Clin. Chem., 2006, 52, 2124-2125.
[174]
Zerwekh, J.E. Blood biomarkers of vitamin D status. Am. J. Clin.
Nutr., 2008, 87(Suppl), S 1087-S1091..
[175]
Lensmeyer, G.L.; Wiebe, D.A.; Binkley, N.; Drezner, M.K. HPLC method for 25-hydroxyvitamin D measurement: Comparison with contemporary assays. Clin. Chem., 2006, 52, 1120-1126.
[176]
Hollis, B.W.; Horst, R.L. The assessment of circulating 25(OH)D and 1, 25(OH)2D: Where we are and where we are going. J. Steroid Biochem. Mol. Biol., 2007, 103, 473-476.
[177]
Carter, G.D.; Jones, J.C. Use of a common standard improves the performance of liquid chromatography-tandem mass spectrometry methods for serum 25-hydroxyvitamin-D. Ann. Clin. Biochem., 2009, 46, 79-81.
[178]
Enko, D.; Kriegshäuser, G.; Stolba, R.; Worf, E.; Halwachs-Baumann, G. Method evaluation study of a new generation of vitamin D assays. Biochem. Med. (Zagreb), 2015, 25, 203-212.
[179]
Eliades, M.; Spyrou, E. Vitamin D: a new player in non-alcoholic fatty liver disease? World J. Gastroenterol., 2015, 21, 1718-1727.
[180]
Stokes, C.S.; Volmer, D.A.; Grünhage, F.; Lammert, F. Vitamin D in chronic liver disease. Liver Int., 2013, 33, 338-352.
[181]
Agmon-Levin, N.; Kopilov, R.; Selmi, C.; Nussinovitch, U.; Sánchez-Castañón, M.; López-Hoyos, M.; Amital, H.; Kivity, S.; Gershwin, E.M.; Shoenfeld, Y. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol. Res., 2015, 61, 141-146.
[182]
Petta, S.; Cammà, C.; Scazzone, C.; Tripodo, C.; Di Marco, V.; Bono, A.; Cabibi, D.; Licata, G.; Porcasi, R.; Marchesini, G.; Craxí, A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51, 1158-1167.
[183]
Grünhage, F.; Hochrath, K.; Krawczyk, M.; Höblinger, A.; Obermayer-Pietsch, B.; Geisel, J.; Trauner, M.; Sauerbruch, T.; Lammert, F. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology, 2012, 5, 1883-1891.
[184]
Pilz, S.; Putz-Bankuti, C.; Gaksch, M.; Spindelboeck, W.; Haselberger, M.; Rainer, F.; Posch, A.; Kreuzer, P.; Stojakovic, T.; Stadlbauer, V.; Obermayer-Pietsch, B.; Stauber, R.E. Effects of Vitamin D supplementation on serum 25-Hydroxyvitamin D concentrations in cirrhotic patients: A randomized controlled trial. Nutrients, 2016, 8, E278.
[185]
Arteh, J.; Narra, S.; Nair, S. Prevalence of vitamin D deficiency in chronic liver disease. Dig. Dis. Sci., 2010, 55, 2624-2628.
[186]
Fisher, L.; Fisher, A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol., 2007, 5, 513-520.
[187]
Monegal, A.; Navasa, M.; Guanabens, N.; Peris, P.; Pons, F.; Martinez de Osaba, M.J.; Rimola, A.; Rodés, J.; Muñoz-Gómez, J. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif. Tissue Int., 1997, 60, 148-154.
[188]
Miroliaee, A.; Nasiri-Toosi, M.; Khalilzadeh, O.; Esteghamati, A.; Abdollahi, A.; Mazloumi, M. Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: A cross-sectional study. Hepatol. Int., 2010, 4, 634-640.
[189]
Rode, A.; Fourlanos, S.; Nicoll, A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol. Clin. Biol., 2010, 34, 618-620.
[190]
Putz-Bankuti, C.; Pilz, S.; Stojakovic, T.; Pilz, S.; Stojakovic, T.; Scharnagl, H.; Pieber, T.R.; Trauner, M.; Obermayer-Pietsch, B. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int., 2012, 32, 845-851.
[191]
Crawford, B.A.L.; Kam, C.; Donaghy, A.J.; Mccaughan, G.W. The heterogeneity of bone disease in cirrhosis: A multi-variate analysis. Osteoporos. Int., 2003, 14, 987-994.
[192]
Bitetto, D.; Fattovich, G.; Fabris, C.; Ceriani, E.; Falleti, E.; Fornasiere, E.E.; Pasino, M.; Ieluzzi, D.; Cussigh, A.; Cmet, S.; Pirisi, M.; Toniutto, P. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology, 2011, 53, 1118-1126.
[193]
Malham, M.; Jørgensen, S.P.; Ott, P.; Agnholt, J.; Vilstrup, H.; Borre, M.; Dahlerup, J.F. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J. Gastroenterol., 2011, 17, 922-925.
[194]
Lange, C.M.; Bojunga, J.; Ramos-Lopez, E.; von Wagner, M.; Hassler, A.; Vermehren, J.; Herrmann, E.; Badenhoop, K.; Zeuzem, S.; Sarrazin, C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol., 2011, 54, 887-893.
[195]
Fisher, L.; Byrnes, E.; Fisher, A.A. Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. Nutr. Res., 2009, 29, 676-683.
[196]
Ratziu, V.; Bugianesi, E.; Dixon, J.; Fassio, E.; Ekstedt, M.; Charlotte, F.; Kechagias, S.; Poynard, T.; Olsson, R. Histological progression of non-alcoholic fatty liver disease: A critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther., 2007, 26, 821-830.
[197]
Musso, G.; Gambino, R.; Cassader, M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes. Rev., 2010, 11, 430-445.
[198]
Saadeh, S.; Younossi, Z.M.; Remer, E.M.; Gramlich, T.; Ong, J.P.; Hurley, M.; Mullen, K.D.; Cooper, J.N.; Sheridan, M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 745-750.
[199]
Strauss, S.; Gavish, E.; Gottlieb, P.; Katsnelson, L. Interobserver¶
and intraobserver variability in the sonographic assessment of fatty
liver. Am. J. Roentgenol., 2007, 189, W320-323.
[200]
Reeder, S.B.; Cruite, I.; Hamilton, G.; Sirlin, C.B. Quantitative¶
assessment of liver fat with magnetic resonance imaging and spectroscopy J. Magn. Reson. Imaging., 2011, 34, 729-749.
[201]
Limanond, P.; Raman, S.S.; Lassman, C.; Sayre, J.; Ghobrial, R.M.; Busuttil, R.W.; Saab, S.; Lu, D.S. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology, 2004, 230, 276-280.
[202]
Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.
[203]
Strauss, R.S.; Barlow, S.E.; Dietz, W.H. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J. Pediatr., 2000, 136, 727-733.
[204]
Pacifico, L.; Ferraro, F.; Bonci, E.; Anania, C.; Romaggioli, S.; Chiesa, C. Upper limit of normal for alanine aminotransferase: quo vadis? Clin. Chim. Acta, 2013, 422, 29-39.
[205]
Wortsman, J.; Matsuoka, L.Y.; Chen, T.C.; Lu, Z.; Holick, M.F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr., 2000, 72, 690-693.
[206]
Amato, M.C.; Guarnotta, V.; Giordano, C. Body composition assessment for the definition of cardiometabolic risk. J. Endocrinol. Invest., 2013, 36, 537-543.
[207]
Shen, W.; Wang, Z.; Punyanita, M.; Lei, J.; Sinav, A.; Kral, J.G.; Imielinska, C.; Ross, R.; Heymsfield, S.B. Adipose tissue quantification by imaging methods: A proposed classification. Obes. Res., 2003, 11, 5-16.
[208]
Shuster, A.; Patlas, M.; Pinthus, J.H.; Mourtzakis, M. The clinical importance of visceral adiposity: A critical review of methods for visceral adipose tissue analysis. Br. J. Radiol., 2012, 85, 1-10.
[209]
Kaul, S.; Rothney, M.P.; Peters, D.M.; Wacker, W.K.; Davis, C.E.; Shapiro, M.D.; Ergun, D.L. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity , 2012, 20, 1313-1318.
[210]
Bredella, M.A.; Ghomi, R.H.; Thomas, B.J.; Torriani, M.; Brick, D.J.; Gerweck, A.V.; Misra, M.; Klibanski, A.; Miller, K.K. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity , 2010, 18, 2227-2233.
[211]
Bredella, M.A.; Gill, C.M.; Keating, L.K.; Torriani, M.; Anderson, E.J.; Punyanitya, M.; Wilson, K.E.; Kelly, T.L.; Miller, K.K. Assessment of abdominal fat compartments using DXA in premenopausal women from anorexia nervosa to morbid obesity. Obesity , 2013, 21, 2458-2464.
[212]
Fosbøl, M.Ø.; Zerahn, B. Contemporary methods of body composition measurement. Clin. Physiol. Funct. Imaging, 2015, 35, 81-97.
[213]
Greenfield, J.R.; Samaras, K.; Chisholm, D.J.; Campbell, L.V. Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography. Obes. Res., 2002, 10, 260-265.
[214]
Wang, X.; Li, W.; Zhang, Y.; Yang, Y.; Quin, G. Association between vitamin D and non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis: results from a meta-analysis. Int. J. Clin. Exp. Med., 2015, 8, 17221-17234.
[215]
Jaruvongvanich, V.; Ahuja, W.; Sanguankeo, A.; Wijarnpreecha, K.; Upala, S. Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig. Liver Dis., 2017, 49, 618-622.
[216]
Papapostoli, I.; Lammert, F.; Stokes, C.S. Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP). J. Gastrointestin. Liver Dis., 2016, 25, 175-181.
[217]
Barchetta, I.; Del Ben, M.; Angelico, F.; Di Martino, M.; Fraioli, A.; La Torre, G.; Saulle, R.; Perri, L.; Morini, S.; Tiberti, C.; Bertoccini, L.; Cimini, F.A.; Panimolle, F.; Catalano, C.; Baroni, M.G.; Cavallo, M.G. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med., 2016, 14, 92.
[218]
Foroughi, M.; Maghsoudi, Z.; Ghiasvand, R.; Iraj, B.; Askari, G. Effect of Vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. Int. J. Prev. Med., 2014, 5, 969-975.
[219]
Sharifi, N. Amani., R; Hajiani, E.; Cheraghian, B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine, 2014, 47, 70-80.
[220]
Kitson, M.T.; Pham, A.; Gordon, A.; Kemp, W.; Roberts, S.K. High-dose vitamin D supplementation and liver histology in NASH. Gut, 2016, 65, 717-718.
[221]
Luger, M.; Kruschitz, R.; Kienbacher, C.; Traussnigg, S.; Langer, F.B.; Prager, G.; Schindler, K.; Kallay, E.; Hoppichler, F.; Trauner, M.; Krebs, M.; Marculescu, R.; Ludvik, B. Vitamin D3 loading is superior to conventional supplementation after weight loss surgery in vitamin d-deficient morbidly obese patients: A double-blind randomized placebo-controlled trial. Obes. Surg., 2017, 27, 1196-1207.
[222]
Bergman, P.; Lindh, A.U.; Björkhem-Bergman, L.; Lindh, J.D. Vitamin D and respiratory tract infections: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 2013, 8, e65835.
[223]
Romagnoli, E.; Carnevale, V.; Biondi, P.; Minisola, S. Vitamin D supplementation: When and how? J. Endocrinol. Invest., 2014, 37, 603-607.
Download PDF Flyer